The Gynecological Cancer Associated Thrombosis (GynCAT) Study
Development and Validation of a Risk Prediction Model for Venous Thromboembolism in Gynecological Cancer Patients Undergoing Systemic Antineoplastic Treatment: The Gynecological Cancer Associated Thrombosis (GynCAT) Study
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
1,800 participants
Apr 15, 2024
OBSERVATIONAL
Conditions
Summary
GynCAT is a prospective cohort study that will be conducted on female patients with gynecologic malignancies scheduled for systemic antineoplastic treatment, aiming at development and validation of a Risk Assessment Model (RAM) for Venous Thromboembolism (VTE) in this specific population.
Eligibility
Inclusion Criteria5
- Female sex;
- Diagnosis of gynecologic neoplasm (ovarian, tubal, uterine, cervical, vaginal, vulvar neoplasm);
- Planned new line of systemic antineoplastic treatment;
- Age of 18 years or older;
- Accordance of Informed Consent.
Exclusion Criteria3
- Pregnant or breastfeeding women;
- Indication to receive therapeutic dose anticoagulant therapy (e.g., atrial fibrillation, mechanical heart valve);
- Diagnosis of symptomatic VTE at the time of screening for enrollment.
Interventions
Prescription of pharmacological thromboprophylaxis according to current clinical practice and international guidelines recommendation
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06284343